DeCure for Charcot-Marie-Tooth disease axonal type 2U
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for Charcot-Marie-Tooth disease axonal type 2U — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCharcot-Marie-Tooth disease axonal type 2U maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for charcot-marie-tooth disease axonal type 2u is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
DNA polymerase gamma, catalytic subunit (POLG) — POLG is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet dcpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8D33 · 2.46 Å · ligand 2'-DEOXYCYTIDINE-5'-TRIPHOSPHATE (DCP). Experimental structure, not a prediction.
What the evidence adds up to
A 2024 case report describes a patient with an intermediate phenotype between Charcot-Marie-Tooth disease type 2Z and DIGFAN (developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy), associated with a novel MORC2 variant. The same report notes that the genotype–phenotype correlation in MORC2-related disorders is complex and that the same mutation can cause a variety of phenotypes. No other abstracts in this set report any drug intervention, clinical trial, or treatment outcome for axonal type 2U or any other CMT subtype.
A separate 2024 review states that Charcot-Marie-Tooth disease remains a difficult problem in terms of accurate diagnosis and effective treatment, despite significant progress in medicine. It provides basic information on diagnosis, clinical picture, and treatment methods but reports no specific efficacy data, survival figures, or response rates for any therapy. A 1994 article on orthotic management presents four case studies with different clinical pictures and discusses muscle grades and gait patterns, but again reports no drug treatment or quantitative outcomes.
No abstract in this set provides evidence for any drug being tested in CMT2U or any other CMT subtype. There are no numbers for response rates, survival, or sample sizes from any therapeutic trial. What is still missing is any funded clinical trial specifically for axonal type 2U, any validated patient stratification by MORC2 genotype, and any preclinical or clinical data on a molecular target for this variant.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Human Genome Variation · 2024 · 2 citations · open access
Intermediate phenotype between CMT2Z and DIGFAN associated with a novel MORC2 variant: a case report
AbstractCharcot-Marie-Tooth disease type 2Z is caused by MORC2 mutations and presents with axonal neuropathy. MORC2 mutations can also manifest as developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy (DIGFAN). We report a patient exhibiting an intermediate phenotype between these diseases associated with a novel MORC2 variant. A literature review revealed that the genotype‒phenotype correlation in MORC2-related disorders is complex and that the same mutation can cause a variety of phenotypes.
Академический журнал Западной Сибири · 2024 · 1 citations · open access
Клинический случай болезни Шарко-Мари-Тута
AbstractCharcot-Marie-Tooth disease (CMT) is a rare inherited disorder of the peripheral nervous system characterized by degeneration of the myelin sheath and axial cylinders of nerve fibers.Currently, despite significant progress in medicine, Charcot-Marie-Tooth disease continues to remain a difficult problem in terms of accurate diagnosis and effective treatment.The review provides basic information on the diagnosis, clinical picture of the disease and treatment methods.
JPO Journal of Prosthetics and Orthotics · 1994 · 1 citations
Orthotic Management of Charcot-Marie-Tooth
AbstractCharcot-Marie-Tooth Disease (CMT) is a neurological condition not commonly seen by orthotists. This article will review recent literature on histology, physical symptoms and classifications. Specific physical manifestations are discussed and illustrated. Four case studies are presented with each having a different clinical picture. Muscle grades and gait patterns as well as a knowledge of this disease's natural history will help practitioners to better provide successful orthotic management.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
